Overview of the SYN321 Clinical Study
Clinical developments in the medical field continue to evolve, particularly in treatments targeting knee osteoarthritis. Synartro is at the forefront of these advances with SYN321, its novel intra-articular treatment. Currently, SYN321 is undergoing a Phase 1/2a clinical study, which emphasizes safety, tolerability, pharmacokinetics (PK), and early efficacy signals of the treatment. This exciting study supports Synartro's commitment to innovative healthcare solutions.
Study Initiation and Recruitment
The SYN321 study commenced following approvals from relevant regulatory bodies, illustrating the company's adherence to strict medical guidelines. A total of 35 participants suffering from knee osteoarthritis were enrolled in the study. The recruitment was efficiently completed within four months, encompassing four distinct cohorts: Cohort 1 (n=7), Cohort 2 (n=8), Cohort 3 (n=8), and Cohort 4 (n=12). Each cohort has shown positive engagement within the protocol.
Cohort Progress
As part of the continuous evaluation, Cohorts 1 through 3 have successfully completed their segments of the study as planned. Meanwhile, Cohort 4 remains active, with fortifying follow-up assessments taking place at regular intervals of four and six weeks. This structured approach allows for robust monitoring of participants' responses to SYN321 and ensures data integrity throughout the study timeline.
Safety and Pharmacokinetics Observations
To date, the interim safety data from this clinical study present a positive outlook. Importantly, there have been no reported serious adverse events associated with SYN321, which speaks volumes about the safety profile of this investigational medicinal product. Adverse events observed so far have aligned with common occurrences related to intra-articular injections, thus providing a reassuring backdrop for stakeholders.
Clinical Data Insights
The interim pharmacokinetic (PK) data, specifically Cmax values observed in participants from Cohorts 1 and 2, indicate a very low systemic exposure to diclofenac, which is a component of SYN321. Interestingly, the results reveal that plasma levels of diclofenac-derived by-products have remained below the quantification threshold. This finding is significant as it supports the intended slow-release characteristics of the treatment, aligning with preclinical expectations and augmenting confidence in SYN321's efficacy.
Future Directions for SYN321
As the study progresses, unblinding is scheduled for the second week of March. Following this, comprehensive analyses concerning safety, tolerability, and pharmacokinetic data will be conducted. These results will provide critical insights regarding SYN321's potential as a safe and effective option for knee osteoarthritis. Synartro's dedication to ongoing research exemplifies not only their commitment to innovation but also their concern for patient safety and health advancement.
Contact Information
For additional information about the SYN321 study or other related inquiries, stakeholders can reach out to Magnus Hurst, CFO & acting CEO of Synartro. He can be contacted via telephone at +46 (0) 760 27 44 27.
Frequently Asked Questions
What is SYN321?
SYN321 is an investigational medicinal product developed by Synartro for the treatment of knee osteoarthritis.
What phase is the clinical study for SYN321 currently in?
The clinical study for SYN321 is in Phase 1/2a, focusing on safety, tolerability, and efficacy.
Have there been any serious adverse events reported?
No serious adverse events related to SYN321 have been reported to date.
How many participants are enrolled in the study?
A total of 35 participants with knee osteoarthritis are enrolled in the ongoing clinical study.
What are the expected future steps for the study?
Unblinding of the study is planned for the second week of March, followed by detailed analyses of the results.
